Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 1, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matt Miksic Maintained (XRAY) at Buy with Decreased Target to $67 on, Mar 1st, 2022
Matt Miksic of Credit Suisse, Maintained "DENTSPLY SIRONA Inc." (XRAY) at Buy with Decreased Target from $68 to $67 on, Mar 1st, 2022.
Matt has made no other calls on XRAY in the last 4 months.
There are 2 other peers that have a rating on XRAY. Out of the 2 peers that are also analyzing XRAY, 0 agree with Matt's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matt
- Jeff Johnson of "Baird" Maintained at Buy with Decreased Target to $67 on, Friday, February 18th, 2022
- Erin Wright of "Morgan Stanley" Initiated at Buy and Held Target at $62 on, Monday, January 31st, 2022
